Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Silverman

Showing results (291-300 of 311) with videos related to

Pageof 32
Sort By:
Journal of Thoracic Imaging|May 31, 2019
Cardiac Computed Tomography for Atrial Fibrillation Patients Undergoing Ablation: Implications for the Prediction of Early RecurrenceUllrich Ebersberger, Michael L Bernard, U Joseph Schoepf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2025
Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after BCMA-directed chimeric antigen receptor T cell therapyZachary M Avigan, Jerrel Catlett, Saoirse Bodnar, et al.
The Lancet. Oncology|February 24, 2009
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyPierre Fenaux, Ghulam J Mufti, Eva Hellstrom-Lindberg, et al.
Leukemia|August 1, 2020
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study resultsMichael Heuser, Neil Palmisiano, Ioannis Mantzaris, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2009
Notes from the field: outbreak of 2009 pandemic influenza A (H1N1) virus at a large public university in Delaware, April-May 2009A Danielle Iuliano, Carrie Reed, Alice Guh, et al.
Blood|March 22, 2003
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromesFrancis J Giles, Alison T Stopeck, Lewis R Silverman, et al.
The Journal of Investigative Dermatology|August 21, 2001
The spectrum of pathogenic mutations in SPINK5 in 19 families with Netherton syndrome: implications for mutation detection and first case of prenatal diagnosisE Sprecher, S Chavanas, J J DiGiovanna, et al.
Leukemia & Lymphoma|January 8, 2015
Phase I dose escalation study of lestaurtinib in patients with myelofibrosisElizabeth O Hexner, John Mascarenhas, Josef Prchal, et al.
The Lancet. Oncology|March 13, 2016
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trialGuillermo Garcia-Manero, Pierre Fenaux, Aref Al-Kali, et al.
Leukemia|November 12, 2024
Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort studyDouglas Tremblay, Clifford Csizmar, Courtney D DiNardo, et al.
Pageof 32

Showing results (291-300 of 311) with videos related to

Sort By:
Pageof 32
Journal of Thoracic Imaging|May 31, 2019
Cardiac Computed Tomography for Atrial Fibrillation Patients Undergoing Ablation: Implications for the Prediction of Early RecurrenceUllrich Ebersberger, Michael L Bernard, U Joseph Schoepf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2025
Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after BCMA-directed chimeric antigen receptor T cell therapyZachary M Avigan, Jerrel Catlett, Saoirse Bodnar, et al.
The Lancet. Oncology|February 24, 2009
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyPierre Fenaux, Ghulam J Mufti, Eva Hellstrom-Lindberg, et al.
Leukemia|August 1, 2020
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study resultsMichael Heuser, Neil Palmisiano, Ioannis Mantzaris, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2009
Notes from the field: outbreak of 2009 pandemic influenza A (H1N1) virus at a large public university in Delaware, April-May 2009A Danielle Iuliano, Carrie Reed, Alice Guh, et al.
Blood|March 22, 2003
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromesFrancis J Giles, Alison T Stopeck, Lewis R Silverman, et al.
The Journal of Investigative Dermatology|August 21, 2001
The spectrum of pathogenic mutations in SPINK5 in 19 families with Netherton syndrome: implications for mutation detection and first case of prenatal diagnosisE Sprecher, S Chavanas, J J DiGiovanna, et al.
Leukemia & Lymphoma|January 8, 2015
Phase I dose escalation study of lestaurtinib in patients with myelofibrosisElizabeth O Hexner, John Mascarenhas, Josef Prchal, et al.
The Lancet. Oncology|March 13, 2016
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trialGuillermo Garcia-Manero, Pierre Fenaux, Aref Al-Kali, et al.
Leukemia|November 12, 2024
Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort studyDouglas Tremblay, Clifford Csizmar, Courtney D DiNardo, et al.
Pageof 32